It's approved in Russia, works through GABA without causing dependence, and actually improves cognition while reducing anxiety. Here's what that means and how it works.
Research context only. Selank is approved in Russia for medical use. It is not FDA-approved. All content is educational.
Selank is a synthetic heptapeptide developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. It's derived from tuftsin — a naturally occurring immune-modulating tetrapeptide — with modifications that extend its stability and add anxiolytic properties.
Unlike most research peptides that exist only in preclinical or gray-market territory, Selank is actually approved and prescribed in Russia and some CIS countries for the treatment of anxiety disorders and as a nootropic. It's been in clinical use in Russia since the 1990s, which gives it a meaningful real-world safety and efficacy track record — even if that data hasn't gone through Western regulatory review.
The one-line version: Selank is a peptide anxiolytic that reduces anxiety and improves cognitive function without sedation, dependence, or the withdrawal issues that characterize benzodiazepines. It works through GABA modulation and BDNF upregulation — a dual mechanism that produces anxiety relief plus cognitive enhancement simultaneously.
Selank modulates GABA-A receptors — the same receptors that benzodiazepines act on. However, unlike benzos which non-selectively enhance GABA signaling (causing sedation and dependence), Selank appears to modulate specific GABA-A subunits in ways that produce anxiolysis without the sedative or addictive profile.
Selank increases brain-derived neurotrophic factor (BDNF) expression. BDNF supports neuroplasticity, memory consolidation, and learning. This is the mechanism behind its cognitive enhancement effects — and explains why users report both reduced anxiety AND improved mental performance, rather than the cognitive blunting typical of sedative anxiolytics.
Selank stabilizes enkephalin levels by inhibiting enkephalinase — the enzyme that breaks down these endogenous opioid peptides. Enkephalins modulate stress responses and emotional processing, contributing to Selank's anxiolytic effect through a second distinct pathway.
Selank downregulates IL-6 and regulates other inflammatory cytokines. Chronic inflammation is associated with anxiety and mood disorders. The anti-inflammatory component may be part of why Selank shows benefits in stress-related conditions beyond acute anxiety.
The key advantage over benzodiazepines: Benzos work by globally enhancing GABAergic inhibition — which reduces anxiety but also impairs memory, causes sedation, and creates physical dependence. Selank's more selective mechanism produces anxiety relief without cognitive impairment. It can actually improve cognitive performance while reducing anxiety — something no benzodiazepine achieves.
Russian clinical trials showed Selank's efficacy for generalized anxiety disorder comparable to benzodiazepines, with significantly better tolerability and no evidence of physical dependence. Cognitive studies showed improved attention, working memory, and learning in both anxious and healthy subjects.
Western animal studies have confirmed the BDNF upregulation and anxiolytic mechanisms independently of the Russian data. The compound has been reproducibly shown to reduce anxiety behavior in rodent models without impairing performance on cognitive tasks — something that distinguishes it sharply from sedative anxiolytics.
Selank's side effect profile from Russian clinical use is notably mild. Decades of clinical prescribing haven't produced significant safety signals:
Selank is not a benzodiazepine and doesn't work by globally potentiating GABA. The mechanism is more selective, the cognitive profile is the opposite (enhancement rather than impairment), and there's no dependence. Describing it as 'a weak benzo' misses what makes it mechanistically distinct.
Intranasal delivery for CNS-active peptides is well-established. The nasal mucosa provides direct access to the CNS via the olfactory pathway. Russian clinical trials used intranasal Selank as the primary delivery route — and it was effective enough to earn drug approval. It works.
Selank is studied in cycles. The anxiety-reducing effects don't require continuous use — short cycles produce meaningful benefits. Chronic continuous use is not how the compound was clinically validated, and cycled use reduces any theoretical tolerance development.
COA-verified vendor pricing with promo codes and reconstitution guide.
View Pricing → Dosage Calculator